Loading...
•
Sep 30, 2024
Rhythm Pharmaceuticals Q3 2024 Earnings Report
Reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
Rhythm Pharmaceuticals reported Q3 2024 net revenue of $33.3 million from global sales of IMCIVREE. The company's cash position is expected to support operations into 2026.
Net revenue from global sales of IMCIVREE® (setmelanotide) was $33.3 million.
Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access program.
Top-line data readout for Phase 3 trial evaluating setmelanotide in 120 patients with acquired hypothalamic obesity is on track for 1H 2025.
Cash on-hand is expected to support planned operations into 2026.
Revenue by Segment
Forward Guidance
Rhythm reduced its anticipated Non-GAAP Operating Expenses to approximately $245 million to $255 million for the year ending December 31, 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...